Olprinone: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
'''Olprinone''' is a | == Olprinone == | ||
[[File:Olprinone.svg|thumb|right|Chemical structure of Olprinone]] | |||
'''Olprinone''' is a [[phosphodiesterase inhibitor]] used primarily in the management of [[heart failure]]. It is known for its ability to increase [[cardiac output]] and improve [[hemodynamics]] in patients with [[congestive heart failure]]. | |||
== Mechanism of Action == | == Mechanism of Action == | ||
Olprinone works by inhibiting the enzyme [[phosphodiesterase 3]] (PDE3), which leads to an increase in intracellular [[cyclic adenosine monophosphate]] (cAMP) levels. This increase in cAMP results in enhanced [[calcium]] influx into [[cardiac muscle]] cells, thereby improving [[myocardial contractility]]. Additionally, olprinone causes [[vasodilation]] by relaxing [[vascular smooth muscle]], which reduces [[afterload]] and [[preload]] on the heart. | |||
== Clinical | == Clinical Uses == | ||
Olprinone is used in the treatment of | Olprinone is primarily used in the treatment of acute [[heart failure]] and is often administered in a [[hospital]] setting. It is particularly useful in patients who require short-term management of heart failure symptoms. The drug is administered intravenously, allowing for rapid onset of action. | ||
== Side Effects == | == Side Effects == | ||
Common side effects of olprinone include [[hypotension]], [[arrhythmias]], and [[headache]]. Due to its vasodilatory effects, olprinone can cause a significant drop in [[blood pressure]], which needs to be monitored closely during treatment. Patients may also experience [[tachycardia]] or other [[cardiac arrhythmias]] as a result of increased myocardial contractility. | |||
== Pharmacokinetics == | |||
Olprinone is metabolized in the [[liver]] and excreted primarily through the [[kidneys]]. It has a relatively short half-life, which necessitates continuous intravenous infusion for sustained therapeutic effects. The drug's pharmacokinetics can be affected by [[renal impairment]], requiring dose adjustments in patients with compromised kidney function. | |||
== Related Pages == | |||
[[ | * [[Phosphodiesterase inhibitor]] | ||
[[ | * [[Heart failure]] | ||
[[ | * [[Cardiac output]] | ||
* [[Vasodilation]] | |||
[[Category:Cardiovascular drugs]] | |||
[[Category:Phosphodiesterase inhibitors]] | |||
Latest revision as of 03:52, 13 February 2025
Olprinone[edit]
Olprinone is a phosphodiesterase inhibitor used primarily in the management of heart failure. It is known for its ability to increase cardiac output and improve hemodynamics in patients with congestive heart failure.
Mechanism of Action[edit]
Olprinone works by inhibiting the enzyme phosphodiesterase 3 (PDE3), which leads to an increase in intracellular cyclic adenosine monophosphate (cAMP) levels. This increase in cAMP results in enhanced calcium influx into cardiac muscle cells, thereby improving myocardial contractility. Additionally, olprinone causes vasodilation by relaxing vascular smooth muscle, which reduces afterload and preload on the heart.
Clinical Uses[edit]
Olprinone is primarily used in the treatment of acute heart failure and is often administered in a hospital setting. It is particularly useful in patients who require short-term management of heart failure symptoms. The drug is administered intravenously, allowing for rapid onset of action.
Side Effects[edit]
Common side effects of olprinone include hypotension, arrhythmias, and headache. Due to its vasodilatory effects, olprinone can cause a significant drop in blood pressure, which needs to be monitored closely during treatment. Patients may also experience tachycardia or other cardiac arrhythmias as a result of increased myocardial contractility.
Pharmacokinetics[edit]
Olprinone is metabolized in the liver and excreted primarily through the kidneys. It has a relatively short half-life, which necessitates continuous intravenous infusion for sustained therapeutic effects. The drug's pharmacokinetics can be affected by renal impairment, requiring dose adjustments in patients with compromised kidney function.
